These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 11687970)
1. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Clarke P; Meintzer SM; Spalding AC; Johnson GL; Tyler KL Oncogene; 2001 Oct; 20(47):6910-9. PubMed ID: 11687970 [TBL] [Abstract][Full Text] [Related]
2. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Sun SY; Yue P; Hong WK; Lotan R Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424 [TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726 [TBL] [Abstract][Full Text] [Related]
7. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
11. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780 [TBL] [Abstract][Full Text] [Related]
12. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Seol DW; Li J; Seol MH; Park SY; Talanian RV; Billiar TR Cancer Res; 2001 Feb; 61(3):1138-43. PubMed ID: 11221844 [TBL] [Abstract][Full Text] [Related]
13. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639 [TBL] [Abstract][Full Text] [Related]
14. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Yang X; Merchant MS; Romero ME; Tsokos M; Wexler LH; Kontny U; Mackall CL; Thiele CJ Cancer Res; 2003 Mar; 63(5):1122-9. PubMed ID: 12615731 [TBL] [Abstract][Full Text] [Related]
15. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Chen X; Kandasamy K; Srivastava RK Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723 [TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135 [TBL] [Abstract][Full Text] [Related]
17. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Voelkel-Johnson C; King DL; Norris JS Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034 [TBL] [Abstract][Full Text] [Related]
18. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Fulda S; Debatin KM Oncogene; 2002 Apr; 21(15):2295-308. PubMed ID: 11948413 [TBL] [Abstract][Full Text] [Related]
19. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
20. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]